Published on January 18, 2010 at 3:32 AM
Karolinska Development AB (publ),
and BioChromix AB announced today the formation of BioChromix Pharma AB, a
new company working to develop a novel Alzheimer treatment with its unique
knowledge of molecular chemistry. Karolinska Development will initially take
28 percent ownership in the new company.
"We are very excited about BioChromix Pharma as they have a novel
approach that targets the cause of the disease. This is an important addition
to our portfolio", says Conny Bogentoft, CEO of Karolinska Development.
"We have a clear goal - to bring our lead product candidates for
Alzheimer's disease to the market. Being part of the Karolinska Development
portfolio, will provided direct access to a broad network of key competencies
and resources in the pharmaceutical industry which will be of great
importance for us in order to succeed", says Peter Asberg, CEO of BioChromix
Pharma AB.
SOURCE Karolinska Development AB (publ), and BioChromix AB